Hemogenyx Pharmaceuticals (HEMO) Competitors

Open Orphan (LON:ORPH) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, community ranking, analyst recommendations and institutional ownership.

Does the media refer more to ORPH or HEMO?

In the previous week, Open Orphan had 7 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 8 mentions for Open Orphan and 1 mentions for Hemogenyx Pharmaceuticals. Open Orphan's average media sentiment score of 0.56 beat Hemogenyx Pharmaceuticals' score of 0.00 indicating that Open Orphan is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Open Orphan	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Hemogenyx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor ORPH or HEMO?

Hemogenyx Pharmaceuticals received 55 more outperform votes than Open Orphan when rated by MarketBeat users. Likewise, 57.89% of users gave Hemogenyx Pharmaceuticals an outperform vote while only 0.00% of users gave Open Orphan an outperform vote.

Company	Underperform	Outperform
Open Orphan	Outperform Votes No Votes	Underperform Votes 2 100.00%
Hemogenyx Pharmaceuticals	Outperform Votes 55 57.89%	Underperform Votes 40 42.11%

Is ORPH or HEMO more profitable?

Open Orphan's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Open Orphan	N/A	N/A	N/A
Hemogenyx Pharmaceuticals	N/A	-155.97%	-37.79%

Do analysts prefer ORPH or HEMO?

Given Open Orphan's higher probable upside, analysts plainly believe Open Orphan is more favorable than Hemogenyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Open Orphan	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Hemogenyx Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Which has preferable valuation & earnings, ORPH or HEMO?

Open Orphan has higher revenue and earnings than Hemogenyx Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Open Orphan	£34.71M	0.00	N/A	N/A	N/A
Hemogenyx Pharmaceuticals	N/A	N/A	-£5.18M	-£0.01	-132.50

Do insiders & institutionals believe in ORPH or HEMO?

0.8% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 10.7% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Open Orphan beats Hemogenyx Pharmaceuticals on 7 of the 11 factors compared between the two stocks.